ATTENTION/WARNING - NE PAS DÉPOSER ICI/DO NOT SUBMIT HERE

Ceci est la version de TEST de DIAL.mem. Veuillez ne pas soumettre votre mémoire sur ce site mais bien à l'URL suivante: 'https://thesis.dial.uclouvain.be'.
This is the TEST version of DIAL.mem. Please use the following URL to submit your master thesis: 'https://thesis.dial.uclouvain.be'.
 

Evaluation of the situation regarding gender parity in a large pharmaceutical company

Leclercq, Pauline
(2020)

Files

LECLERCQ_40461800_2020.pdf
  • Closed access
  • Adobe PDF
  • 1.24 MB

Details

Supervisors
Jammaers, Eline
Faculty
Louvain School of Management
Degree label
Master [60] en sciences de gestion (horaire décalé)
Abstract
This study analyzes the situation regarding gender parity in leadership in a leading pharmaceutical company, GlaxoSmithKline [GSK] Vaccines. A recent European Union [EU] report (European Commission, 2019) revealed that, despite a clear ambition to achieve gender parity, only recommendations are suggested to the countries and ultimately applied by them with more or less engagement or not applied at all. In this context, companies that are actively involved can make a difference to achieve gender parity objectives. The types of initiatives in place and outcomes differ from one firm to another. In the pharmaceutical companies, gender parity is often achieved at the overall personnel count and even if behind such apparent equality lurk important ‘bottle neck’-problems (e.g. lack of women in leadership positions), the situation is better than in other sectors.